Trial Profile
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With beta-Thalassemia Major: Once-Daily Versus Twice-Daily Administration.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Pharmacokinetics
- 27 Nov 2015 New trial record